DDInter438 DDInter596
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Conivaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Conivaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Conivaptan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Conivaptan {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Conivaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Conivaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Conivaptan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Conivaptan {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Conivaptan {u} (Compound) resembles {v} (Compound) Tolvaptan
Tolvaptan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Conivaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Doxorubicin (Compound)
Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxorubicin (Compound)
Conivaptan (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Doxorubicin (Compound)
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Daunorubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Conivaptan (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Epirubicin (Compound) and Epirubicin (Compound) resembles Doxorubicin (Compound)
Conivaptan (Compound) resembles Tolvaptan (Compound) and Tolvaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxorubicin (Compound)
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Idarubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Doxorubicin (Compound)